News

Vivus’ Experimental PAH Therapy VI-0106 Shows Potential in Phase 1 Study

Vivus Biopharmaceuticals’ investigative therapy VI-0106 for pulmonary arterial hypertension (PAH) showed a favorable pharmacokinetic profile in healthy volunteers in a Phase 1 trial. Pharmacokinetics refers to how a medication is absorbed, distributed, metabolized, and eliminated from the body. VI-0106 is a soft gel formulation of tacrolimus, an immunosuppressant under…

Surgical Removal of Blood Clots Reverses PH But Not Sleep Issues in CTEPH Patients, Study Finds

Surgery to remove blood clots from the arteries improves pulmonary hypertension (PH) symptoms but not underlying sleep disorders in patients with chronic thromboembolic pulmonary hypertension (CTEPH), according to a study. The study, “Chronic thromboembolic pulmonary hypertension: Reversal of pulmonary hypertension but not sleep-disordered breathing following…